PTIXW 0.01 Protagenic Therapeutics, Inc.
| Range: | 0.0149-0.0149 | Vol Avg: | 0 | Last Div: | 0 | Changes: | 0.01 |
| Beta: | 0.28 | Cap: | 0.00B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Tue Apr 27 2021 | Empoloyees: | 1 | ||
| CUSIP: | 74365N111 | CIK: | 0001022899 | ISIN: | US74365N1110 | Country: | US |
| CEO: | Dr. Garo H. Armen Ph.D. | Website: | https://www.protagenic.com | ||||
Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow